Differential diagnosis and therapeutic options for ambiguous genitalia

Current Opinion in Endocrinology and Diabetes

Volumn 5, Issue 1, 1998, Pages 3-10

  Vogiatzi, Maria G ^a   New, Maria I ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN INSENSITIVITY SYNDROME; DIFFERENTIAL DIAGNOSIS; FEMALE; FEMALE PSEUDOHERMAPHRODITISM; HUMAN; KARYOTYPE; MALE; MALE PSEUDOHERMAPHRODITISM; MOLECULAR BIOLOGY; REVIEW; SEX DETERMINATION; SEXUAL DEVELOPMENT; TRUE HERMAPHRODITISM;

EID: 0031948950     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199802000-00002     Document Type: Review

References (70)

1. Sinclair AH, Berta P, Palmer MS, Hawkins JR, Griffiths BL, Smith MJ, Foster JW, Frischauf AM, Lovell-Badge R, Goodfellow PN: A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 1990, 346:240-244.
2. Harley VR, Jackson DI, Hextall PJ, Hawkins JR, Berkovitz GD, Sockanathan S, Lovell-Badge R, Goodfellow PN: DNA binding activity of recombinant SRY from normal males and XY females. Science 1992, 255:453-456.
3. Harley VR, Lovell-Badge R, Goodfellow PN: Definition of a consensus DNA binding site for SRY. Nucleic Acids Res 1994, 22:1500-1501.
4. Prior HM, Walter MA: SOX genes: architects of development. Mol Med 1996, 2:405-412.
5. MacLean HE, Wame GL, Zajac JD: Intersex disorders: shedding light •• on male sexual differentiation beyond SRY. Clin Endocrinol 1997, 46:101-108. Reviews genes involved in testicular differentiation.
6. Foster JW, Dominguez-Steglich MA, Guioli S, Kwok C, Weller PA, Stevanovic M, Weissenbach J, Mansour S, Young ID, Goodfellow PN, Brook JD, Schafer AJ: Campomellc dysplasia and autosomal sex reversal caused by mutations in an SRY related gene. Nature 1994, 372:525-530.
7. Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, Pasantes J, Bricarelli FD, Keutel J, Hustert E, Wolf U, Tommerup N, Schempp W, Scherer G: Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell 1994, 79:1111-1120.
8. Wright E, Hargrave MR, Christiansen J, Cooper L, Kun J, Evans T, Gangadharan U, Greenfield A, Koopman P: The Sry-related gene SOX9 is expressed during chondrogenesis in mouse embryos. Nature Gene 1995, 9:15-20.
9. Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE, Houghton DC, Junien C, Habib R, Fouser L, Fine RN, Silverman BL, Haber DA, Housman D: Germline mutations in the Wilm's tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991, 67:437-447.
10. Bardoni B, Zanaria E, Guioli S, Floridia G, Worley KC, Tonini G, Ferrante E, Chiumello G, McCabe ERB, Fraccaro M, Zuffardi O, Camerino G: A dosage sensitive locus at chromosome Xp21 is involved in male and female sex reversal. Nature Genet 1994, 7:497-501.
11. Koopman P, Munsterberg A, Capel B, Vivian N, Lovell-Badge R: Expression of a candidate sex-determining gene during mouse testis differentiation. Nature 1990, 348:450-452.
12. Shen WH, Moore CC, Ikeda Y, Parker KL, Ingraham HA: Nuclear receptor steroidogenic factor I regulates the Mullerlan inhibiting substance gene: a link to the sex determination cascade. Cell 1994, 77:651-661.
13. Mishina Y, Rey R, Finegold MJ, Matzuk MM, Josso N, Cate RL, Behringer •• RR: Genetic analysis of the Mullerlan-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes Dev 1996, 10:2577-2587. Reports on the phenotype of MIS ligand/MIS receptor mutant mouse, on the phenotype of mouse overexpressing MIS, and on MIS signaling pathway.
14. Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, Maclaughlin DT, Donahoe PK: Developmental expression of a candidate Mullerlan inhibiting substance type II receptor. Endocrinology 1996, 137:160-167.
15. Cohen HL, Shapiro MA, Mandel FS, Shapiro ML: Normal ovaries in neonates and infants: a sonographic study of 77 patients 1 day to 24 months old. Am J Roentgenol 1993, 160:583-586.
16. Secaf E, Hricak H, Gooding CA, Ho VW, Gorczyca DP, Ringertz H, Conte FA, Kogan BA, Grumbach MM: Role of MRI in the evaluation of ambiguous genitalia. Pediatr Radiol 1994, 24:231-235.
17. DeRosa M, Lupoli G, Mennitti M, Zarrilli S, Mirone V, Lombardi G: Congenital bilateral anorchia: clinical, hormonal and imaging study in 12 cases. Andrologia 1996, 28:281-285.
18. Reinhold C, Hricak H, Forstner R, Ascher SM, Bret PM, Meyer WR, Semelka RC: Primary amenorrhea: evaluation with MR imaging. Radiology 1997, 203:383-390.
19. Fuqua JS, Sher ES, Migeon CJ, Berkovitz GD: Assay of plasma testosterone during the first six months of life: importance of chromatographic purification of steroids. Clin Chem 1995, 41:1146-1149.
20. Makela SK, Ellis G: Nonspecificity of a direct 17α-hydroxyprogesterone radioimmunoassay kit when used with samples from neonates. Clin Chem 1988, 34:2070-2075.
21. Honour JW, Brook CGD: Clinical indications for the use of urinary steroid profiles in neonates and children. Ann Clin Biochem 1997, 34:45-54.
22. Forest M: Pattern of the response of testosterone and its precursors to human chorionic gonadotropin stimulation in relation to age in infants and children. J Clin Endocrinol Metab 1979, 49:132-137.
23. Sinnecker G, Kohler S: Sex hormone-binding globulin response to the anabolic steroid stanozolol: evidence for its suitability as a biological androgen sensitivity test. J Clin Endocrinol Metab 1989, 68:1195-1200.
24. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D, MacLaughlin DT: Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996, 81:571-576.
25. Lee MM, Donahoe PK, Silverman BL, Hasegawa T, Hasegawa Y, •• Gustafson ML, Chang Y, MacLaughlin DT: Measurement of serum mullerlan inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med 1997, 336:1480-1486. This study examines the use of MIS concentrations in evaluations of children with anorchia or intersexual disorders, and proposes a diagnostic scheme based on MIS values.
26. Forest MG: Serum mullerian inhibiting substance assay-a new diagnostic test for disorders of gonadal development. N Engl J Med 1997, 336:1519-1521.
27. White PC, Curnow KM, Pascoe L: Disorders of 11β-hydroxylase isoenzymes. Endocr Rev 1994, 15:421-438.
28. Cumow KM, Slutskel L, Vitek J, Cole T, Speiser PW, New MI, White PC, Pascoe I: Mutations in the CYP11B1 gene causing congenital adrenal hyperplasla and hypertension cluster in exons 6, 7, and 8. Proc Natl Acad Sci U S A 1993, 90:4552-4556.
29. Cunniff C, Kratz LE, Moser A, Natowicz MR, Kelley RI: Clinical and • biochemical spectrum of patients with RSH/Smith-Lemli-Opitz syndrome and abnormal cholesterol metabolism. Am J Med Genet 1997, 68:263-269. This study describes the clinical and biochemical characteristics of 80 patients with Smith-Lemli-Opritz syndrome and elevated levels of 7-dehydrocholesterol.
30. Sharp P, Haan E, Fletcher JM, Khong TY, Carey WF: First trimester diagnosis of Smith-Lemli-Opitz syndrome. Prenat Diagn 1997, 17:355-361.
31. Irons M, Elias ER, Abuelo D, Bull MJ, Greene CL, Johnson VP, Keppel L, • Schanen C, Tint GS, Salen G: Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. Am J Med Genet 1997, 68:311-314. This study reports improvement on growth and neurodevelopmental status in 11 patients with Smith-Lemli-Opitz syndrome treated with cholesterol and one or more bile acids.
32. Saldanha PH, Arnhold U, Mendonca BB, Bloise W, Toledo SP: A clinicogenetic investigation of Leydig cell hypoplasla. Am J Med Genet 1987, 26:337-344.
33. Laue L, Wu S-M, Kudo M, Hsueh AJW, Cutler GB, Griffin JE, Wilson JD, Brain C, Berry AC, Grant DB, Chan W-J: A nonsense mutation of the human luteinizing hormone receptor gene in Leydig cell hypoplasia. Hum Mol Genet 1995, 4:1429-1433.
34. Burgner DP, Kimnond S, Wallace AM, Young DG, Forest MG, Donaldson MDC: Male pseudohermaphroditism secondary to panhypopituitarism. Arch Dis Child 1996, 75:153-155.
35. Heinrich UE, Bettendorf M, Vecset P: Male pseudohermaphroditism caused by nonsalt-losing congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase (3β-HSD) deficiency. J Steroid Biochem Mol Biol 1993, 45:83-85.
36. Simard J, Rheaume E, Sanchez R, Laflamme N, de Launoit Y, Luu-The V, van Seters AP, Gordon RD, Bettendorf M, Heinrich U, Moshang T, New MI, Labrie F: Molecular basis of congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase deficiency. Mol Endocrinol 1993, 7:716-728.
37. Rheaume E, Simard J, Morel Y, Mebarki F, Zachmann M, Forest MG, New MI, Labrie F: Congenital adrenal hyperplasia due to point mutations in the type II 3β-hydroxysteroid dehydrogenase gene. Nat Genet 1992, 1:239-245.
38. Yanase T, Simpson ER, Waterman MR: 17α-Hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition. Endocr Rev 1991, 12:91-108.
39. Ahlgren R, Yanase T, Simpson ER, Winter JSD, Waterman MR: Compound heterozygous mutation (Arg 239→Stop, Pro 342→Thr) in the CYP17 (P45017μ) gene led to ambiguous external genitalia in a male patient with partial combined 17α-hydroxylase/17,20-lyase deficiency. J Clin Endocrinol Metab 1992, 74:667-672.
40. Miura K, Yasuda K, Yanase T, Yamakita N, Sasano H, Nawata H, Inoue M, Fukaya T, Shizuta Y: Mutation of the cytochrome P-45017 α gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism: with a review of Japanese patients with mutations of CYP17. J Clin Endocrinol Metab 1996, 81:3797-3801.
41. Bose HS, Sugawara T, Strauss JF, Miller WL: The pathophysiology and •• genetics of congenital lipoid adrenal hyperplasia. N Engl J Med 1996, 335:1870-1878. This report demonstrates that lipoid CAH is due to mutations in StAR and proposes a two-hit model of the pathogenesis of lipoid CAH: an initial loss of steroidogenesis due to loss of StAR activity, and a subsequent loss of steroidogenesis, independent of StAR, due to cellular damage from accumulated cholesterol esters.
42. Bose HS, Peskovitz OH, Miller WL: Spontaneous feminization in a • 46XX female patient with congenital lipoid adrenal hyperplasia due to a homozygous frameshift mutation in the steroidogenic acute regulatory protein. J Clin Endocrinol Metab 1997, 82:1511-1515. This case confirms the two-hit model of the pathogenesis of lipoid CAH proposed in the previous reference.
43. Okuyama E, Nishi N, Onishi S, Itoh S, Ishii Y, Miyanaka H, Fujita K, Ichikawa Y: A novel splicing junction mutation in the gene for the steroidogenic acute regulatory protein causes congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab 1997, 82:2337-2342.
44. Rosler A, Belanger A, Labrie F: Mechanism of androgen production in male pseudohermaphroditism due to 17β-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 1992, 75:773-778.
45. Castro-Magana M, Angulo M, Uy J: Male hypogonadism with gynecomastia caused by late-onset deficiency of testicular 17-ketosteroid reductase. N Engl J Med 1993, 328:1297-1301.
46. Wilson JD, Griffin JE, Russell DW: Steroid 5α-reductase 2 deficiency. Endocr Rev 1993, 14:577-593.
47. Sinnecker GHG, Hiort O, Dibbelt L, Albers N, Dorr HG, Hau H, Heinrich U, Hemminghaus M, Hoepffner W, Holder M, Schnabel D, Krus K: Phenotypic classification of male pseudohermaphroditism due to steroid 5αreductase 2 deficiency. Am J Med Genet 1996, 63:223-230.
48. Forti G, Falchetti A, Santoro S, Davis DL, Wilson JD, Russell DW: Steroid 5α-reductase 2 deficiency: virilization in early infancy may be due to partial function of mutant enzyme. Clin Endocrinol 1996, 44:477-482.
49. Cai L-Q, Zhu Y-S, Katz MD, Herrera C, Baez J, deFillo-Ricart M, Shackleton CHL, Imperato-McGinley J: 5α-Reductase 2 gene mutations in the Dominican Republic. J Clin Endocrinol Metab 1996, 81:1730-1735.
50. Canto P, Vilchis F, Chavez B, Mutchinick O, Imperato-McGinley J, Perez-Palacios G, Ulloa-Aguirre A, Mendez JP: Mutations of the 5α-reductase type 2 gene in eight Mexican patients from six different pedigrees with 5α-reductase-2 deficiency. Clin Endocrinol 1997, 46:155-160.
51. Pang S, Levine LS, Chow D, Sagiani F, Saenger P, New MI: Dihydrotestosterone and its relationship to testosterone in infancy and childhood. J Clin Endocrinol Metab 1979, 48:821-826.
52. Hiort O, Willenbring H, Albers N, Hecker W, Engert J, Dibbelt L, Sinnecker • GHG: Molecular genetic analysis and human chorlonic gonadotropin stimulation tests in the diagnosis of prepubertal patients with partial 5α-reductase deficiency. Eur J Pediatr 1996, 155:445-451. This report provides correlations between molecular and hormonal findings in four prepubertal patients with 5α-reductase deficiency and demonstrates that prolonged stimulation with hCG leads to higher testosterone/dihydrotesterone ratios.
53. Quigley CA, De Bellis A, Marschke KB, EI-Awady MK, Wilson EM, French FS: Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995, 16:271-321.
54. Rutgers JL, Scully RE: The androgen insensitivity syndrome (testicular feminization): a clinicopathological study of 43 cases. Int J Gynecol Pathol 1991, 10:126-144.
55. Bale PM, Howard NJ, Wright JE: Male pseudohermaphroditism in XY children with female phenotype. Pediatr Pathol 1992, 12:29-49.
56. Sinnecker G, Kohler S: Sex hormone-binding globulin response to the anabolic steroid stanazol: evidence of its suitability as a biological androgen sensitivity test. J Clin Endocrinol Metab 1989, 68:1195-1200.
57. Bertelloni S, Federico G, Baroncelli GI, Cavallo L, Corsello G, Liotta A, • Rigon F, Saggese G: Biochemical selection of prepubertal patients with androgen insensitivity syndrome by sex hormone-binding globulin response to the human chorionic gonadotropin test. Pediatr Res 1997, 41:266-271. This study reports on the changes in serum SHBG levels after hCG stimulation in prepubertal subjects with AIS (n = 9), in subjects with other causes of male pseudohermaphroditism (n = 8), and in normal subjects (n = 12) and advocates the usefulness of the test in the diagnostic evaluation of AIS.
58. Forrest S, Cotton R, Landegren U, Southern E: How to find all these mutations. Nat Genet 1995, 10:375-376.
59. Hiort O, Sinnecker GHG, Holterhus P-M, Nitsche EM, Kruse K: The clinical and molecular spectrum of androgen insensitivity syndrome. Am J Med Genet 1996, 63:218-222.
60. Weidemann W, Linck B, Haupt H, Mentrup B, Romalo G, Stockklauser K, • Brinkmann AO, Schweikert HU, Spindrler KD: Clinical and biochemical investigations and molecular analysis of subjects with mutations in the androgen receptor gene. Clin Endocrinol 1996, 45:733-739. Examines the relationship between the degree of androgen resistance and the binding parameters of the androgen receptor and the nature of the mutation in the androgen receptor gene.
61. Tincello DG, Saunders PTK, Hodgins MB, Simpson NB, Edwards CRW, Hargreaves TB, Wu FCW: Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone in patients with partial androgen insensitivity syndrome. Clin Endocrinol 1997, 46:497-506.
62. Berkmen F: Persistent mullerian duct syndrome with or without transverse testicular ectopia and testis tumours. Br J Urol 1997, 79:122-126.
63. Damiani D, Fellous M, McElreavey K, Barbaux ESA, Barreto ESA, Dichtchekenian V, Setian N: True hermaphroditism: clinical aspects and molecular studies in 16 cases. Eur J Endocrinol 1997, 136:201-204.
64. Torres L, Lopez M, Mendez JP, Canto P, Cervantes A, Alfaro G, Perez-Palacios G, Erickson RP, Kofman-Alfaro S: Molecular analysis in true hermaphrodites with different karyotypes and similar phenotypes. Am J Med Genet 1996, 63:348-355.
65. Van Wyk J, Gunther DF, Ritzen M, Wedell A, Cutler GB, Migeon CJ, New •• MI: Therapeutic controversies. The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1996, 81:3180-3190. This paper considers the risks and benefits of conventional medical treatment of CAH and other alternative proposed treatment modalities, such as surgical or "medical" adrenalectomy.
66. Di Benedetlo V, Gioviale M, Bagnara V, Cacciaguerra S, Di Benedetto A: The anterior sagittal transanorectal approach: a modified approach to 1-stage clitoral vaginoplasty in severely masculinized female pseudohermaphrodites-preliminary results. J Urol 1997, 157:330-332.
67. Costa EMF, Mendonca BB, Inacio M, Arnhold IJP, Silva FAQ, Lodovici O: • Management of ambiguous genitalia in pseudohermaphrodites: new perspectives on vaginal dilation. Fertil Steril 1997, 67:229-232. This paper evaluates the vaginal size and sexual activity after different techniques of feminization in patients with pseudohermaphroditism.
68. Imperato-McGinley J: 5-Alpha-reductase deficiency. In Current Therapy in Endocrinology and Metabolism, 5th ed. Edited by Bardin CW. St Louis: Mosby-Year Book; 1994:351-354.
69. Katz MD, Kligman I, Cai L-Q, Zhu Y-S, Fratianni CM, Zervoudakis I, • Rosenwaks Z, Imperato-McGinley J: Paternity by intrauterine insemination with sperm from a man with 5α-reductase-2 deficiency. N Engl J Med 1997, 336:994-997. This is a case of paternity by intrauterine insemination in a man with 5α-reductase-2 deficiency.
70. American Academy of Pediatrics, Action Committee for Determining Timing of Elective Surgery on the Genitalia of Male Children: Timing of elective surgery on the genitalia of male children with particular reference to the risks, benefits, and psychological effects of surgery and anesthesia. Pediatrics 1996, 97:590-593.